Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Germline TP53 Testing in Breast Cancers: Why, When and How?

14 Dec 2020

Abstract excerpt

Germline TP53 variants represent a main genetic cause of breast cancers before 31 years of age. Development of cancer multi-gene panels has resulted in an exponential increase of germline TP53 testing in breast cancer patients. Interpretation of TP53 variants, which are mostly missense, is complex and requires excluding clonal haematopoiesis and circulating tumour DNA. In breast cancer patients harbouring...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Genomics and Diagnostics
Share to Cancer-related Molecular Pathways
Share to Genomic variations and chromosomal abnormalities

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 33327514
DOI: 10.3390/cancers12123762

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Germline TP53 Testing in Breast Cancers: Why, When and How?PMID 33327514Read ↗

Germline TP53 pathogenic variants and breast cancer: A narrative review.Semantic proximity Read ↗

Guidelines for the Li–Fraumeni and heritable TP53-related cancer syndromesSemantic proximity Read ↗

Clinical implications of germline mutations in breast cancer: TP53.Semantic proximity Read ↗

Germline testing for breast cancer patients in England: illogical to prioritise grade 1 breast cancer aged 30-39 over grade 3 aged 40-49 years?Semantic proximity Read ↗

Results from London Regional Clinical Genetics services over a 5-year period on germline TP53 testing in women diagnosed with breast cancer at <30 years.Semantic proximity Read ↗

Pathogenic germline TP53 mutations in adult sarcoma patients; implications for treatment and screening – description of an upcoming projectSemantic proximity Read ↗

Surveillance recommendations for patients with germline TP53 mutations.Semantic proximity Read ↗

TP53 germline mutation testing in early-onset breast cancer: findings from a nationwide cohortSemantic proximity Read ↗

Deciphering dual clinical entities associated with TP53 pathogenic variants: Insights from 53,085 HBOC panel analyses in French laboratories.Semantic proximity Read ↗

Apparently "BRCA-related" breast and ovarian cancer patient with germline TP53 mutation.Semantic proximity Read ↗

Suggested application of HER2+ breast tumor phenotype for germline TP53 variant classification within ACMG/AMP guidelines.Semantic proximity Read ↗

The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.